The biobank was used to screen over 500 bispecific antibodies, leading to the identification of MCLA‐158, which is a therapeutic that selectively eliminates LGR5+ cancer stem cells while sparing healthy cells and inhibits metastasis. This evidence concerns the gene LGR5 and cancer.